Immunohistochemical (IHC) analysis of BRAF V600E melanoma patient-derived biopsies highlighted that patients with abundant stromal HGF showed a poorer response to BRAF inhibitors than those lacking stromal HGF [61]. This evidence concerns the gene HGF and melanoma.